Various radiopharmaceuticals with higher tumor specificity have therefore been developed to increase diagnostic accuracy for certain tumor entities, e.g., [68Ga]Ga-PSMA-11 or [18F]F-PSMA-1007 in prostate cancer [126,127], somatostatin receptor-specific tracers for neuroendocrine tumors [128], radiolabeled peptides in brain tumors [129] or [18F]fibroblast activation protein inhibitor (FAPI) for different carcinoma types [130]. Here, FOLH1 is linked to neuroendocrine neoplasm.